Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Jan Holmgren research groups

Cholera toxin, mucosal immunity and development of mucosal vaccines and immunotherapies

Gothenburg University Vaccine Research Centre (GUVAX)

Cholera toxin, mucosal immunity and development of mucosal vaccines and immunotherapies

 

Group leader: Jan Holmgren (professor, M.D., Ph.D.)
Members: Stephen Attridge (Associate professor, Ph.D.), Carl-Fredrik Flach (postdoc, Ph.D.), Michael Lebens (scientist, Ph.D.), Anna Lundgren (shared postdoc, Ph.D.), Jia-Bin Sun (scientist, Ph.D.), Ulf Yrlid (postdoc, Ph.D.), Erik Nygren (Ph.D. student), Johan Wiman (Ph.D. student), Margareta Blomquist (research technician), Bin-Ling Li (research technician, M.D.), Gun Wallerström (research technician)


The mucosal immune system comprises ca 80% of all immunocytes and has developed effective, as yet incompletely understood means for protecting both against mucosal infections and harmful immune responses to ingested or inhaled antigens. There is currently great interest internationally in developing mucosal vaccines against many important microbial pathogens. Mucosally induced tolerance also is a promising form of immunomodulation for treating certain autoimmune diseases and allergies. Our research addresses these closely interlinked areas by studies in which cholera toxin or cholera toxin derivatives are often used as antigens, vectors or immunomodulating agents:


1. Mucosal immunity research aiming at improved ways of mucosal vaccination and immune response steering. We will continue animal research to further define mucosal regulatory mechanisms determining the outcome -- immunity or tolerance -- of local antigen exposure and to develop ways of steering and maximizing the immune response in the desired direction. Specifically, we will continue our efforts to define the role of different subsets of mucosally induced antigen presenting cells (APC) for induction of immunity or tolerance, compare immunization by different mucosal routes focusing on oral and sublingual antigen delivery, and continue our development of mucosal adjuvants including the recently described promising CTB-CpG conjugate.


2. Continued research towards the development of oral vaccines against gastrointestinal infections. We have developed an internationally widely registered oral vaccine (Dukoral®) against cholera with efficacy also against diarrhea caused by enterotoxigenic E.coli (ETEC); this is the only original vaccine ever developed in Scandinavia. The further specific vaccine development objectives are: (1) To develop an oral vaccine against Vibrio cholerae O139, a new cholera serotype with potential to cause another pandemic; (2) To contribute to the development of a specific vaccine against ETEC diarrhea, the most common cause of diarrheal illness in both children in developing countries and in travelers – joint project with A-M Svennerholm et al. and SBL Vaccin; and (3) to advance the understanding and develop means of steering the balance between immune protection and immunopathology in experimental H. pylori infection and immunization as a basis for vaccine development.


3. Research to develop therapeutic vaccines based on oral tolerance induction, including the further development of a promising “vaccine¿ in the treatment of Behcet’s disease. We have developed a novel concept for mucosal tolerance induction based on the use of recombinantly produced CTB fused chemically or genetically to a relevant antigen/tolerogen. This has given very promising results in the prevention and treatment in animal models of autoimmune diseases (e.g. MS-like encephalomyelitis, RA-like arthritis, diabetes and uveitis); IgE- and DTH-mediated allergies; and infection immunopathology (e.g. schistosomiasis). An important breakthrough is that this novel treatment principle now for the first time has been tested clinically with very promising results in patients with Behcet’s disease! Based on this we will now (1) Further develop selected CTB-based fusion proteins for potential immune therapy in Behcet’s disease, diabetes and arteriosclerosis; (2) In animals and humans further define immunological correlates to positive treatment effects; and (3) Further develop the promising initial clinical studies in Behcet’s disease.


Important review papers:
Holmgren J, Czerkinsky C. (2005). Mucosal immunity and vaccines. Nature Med 11: S45-53.


Sanchez J and Holmgren J. (2005) Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin in Immunol 17:388-398.


Raghavan S and Holmgren J. (2005) CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and disease. FEMS Immunol Med Microbiol 44:121-127.

 

Gothenburg University Vaccine Research Centre (GUVAX)

 

Director: Jan Holmgren (MD, PhD, Prof.); Assoc. Director: Ann-Mari Svennerholm (MD, PhD,Prof.)

Gothenburg University (GU) is since long time an internationally recognized centre for vaccine research and development. In the field of mucosal vaccines, most notably against gastrointestinal infections, and in the area of mucosal immunology GU researchers have made internationally acclaimed contributions, including the development of an internationally widely registered oral cholera vaccine (Dukoral®).To provide better resources and a clearer identity for its vaccine research, GU has with financial support from the Knut and Alice Wallenberg foundation established a specific vaccine research institute–Gothenburg University Vaccine Research Institute (GUVAX) – located at the Dep. of Medical Microbiology and Immunology, The Sahlgrenska Academy. GUVAX´s research focuses on vaccine development against selected mucosal infections; research to develop anti-immunopathological vaccines /immunotherapies against autoimmune and allergic diseases based on mucosally induced tolerance; and research to develop therapeutic vaccination strategies against certain forms of cancer. An important generic research line is the elucidation of cells and mechanisms involved in steering the mucosal immunization outcome towards immunity or tolerance and the development of immunomodulating adjuvants for such purposes.

GUVAX collaborates actively with many research groups and units in Sweden and abroad, including active collaboration with many international organisations and institutions engaged in vaccine research.

Important publications:
Holmgren J, Czerkinsky C: Mucosal immunity and vaccines. Nature Med 11: Suppl. S45-S53, 2005.

Sanchez J and Holmgren J: Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 17:388-398, 2005.

Sidansvarig: Dan Baeckström|Sidan uppdaterades: 2014-05-07
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?